American Board of Cosmetic Surgery
American Board of Dermatology
MD, University of Southern California
Residency, General Surgery
University of Southern California Hospital
Fellowship, Procedural Dermatology/Mohs
Mount Sinai Hospital
Teacher of The Year 2011
Mount Sinai School of Medicine Dep. of Dermatology
For Excellence in Resident and Fellow Teaching
Minimal Scar Wound Repair
Intensely interested in minimal scar wound repair, he has done extensive research in this area. In particular, he has focused on the molecular agents involved in fetal scarless wound healing including TGF family of molecules and Fibromodulin. Dr. Khorasani has presented his work at multiple national meetings.
Scar analysis of post Mohs micrographic surgery wounds treated with ablative C02 resurfacing
Using fractal analysis and lacunarity to objectively analyze wounds treated with ablative fractional CO2 laser post surgery.
Khorasani H, Zheng Z, Nguyen C, Zara J, Zhang X, Wang J, Ting K, Soo C. A quantitative approach to scar analysis. The American journal of pathology 2011 Feb; 178(2).
Zheng Z, Nguyen C, Zhang X, Khorasani H, Wang JZ, Zara JN, Chu F, Yin W, Pang S, Le A, Ting K, Soo C. Delayed wound closure in fibromodulin-deficient mice is associated with increased TGF-β3 signaling. The Journal of investigative dermatology 2011 Mar; 131(3).
Chotiner JK, Khorasani H, Nairn AC, O'Dell TJ, Watson JB. Adenylyl cyclase-dependent form of chemical long-term potentiation triggers translational regulation at the elongation step. Neuroscience 2003; 116(3).
Watson JB, Khorasani H, Persson A, Huang KP, Huang FL, O'Dell TJ. Age-related deficits in long-term potentiation are insensitive to hydrogen peroxide: coincidence with enhanced autophosphorylation of Ca2+/calmodulin-dependent protein kinase II. Journal of neuroscience research 2002 Nov; 70(3).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Khorasani did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.